Immunotherapeutic progress and application of bispecific antibody in cancer

Jingyue Kang; Tonglin Sun; Yan Zhang

doi:10.3389/fimmu.2022.1020003

Immunotherapeutic progress and application of bispecific antibody in cancer

Front Immunol. 2022 Oct 20:13:1020003. doi: 10.3389/fimmu.2022.1020003. eCollection 2022.

Authors

Jingyue Kang^{1

2}, Tonglin Sun^{1

3}, Yan Zhang^{1

3}

Affiliations

¹ Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
² State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
³ Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Bispecific antibodies (bsAbs) are artificial antibodies with two distinct antigen-binding sites that can bind to different antigens or different epitopes on the same antigen. Based on a variety of technology platforms currently developed, bsAbs can exhibit different formats and mechanisms of action. The upgrading of antibody technology has promoted the development of bsAbs, which has been effectively used in the treatment of tumors. So far, 7 bsAbs have been approved for marketing in the world, and more than 200 bsAbs are in clinical and preclinical research stages. Here, we summarize the development process of bsAbs, application in tumor treatment and look forward to the challenges in future development.

Keywords: antibody constructs; bispecific antibody; bsAb; clinical trials; tumor immunotherapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific*
Humans
Immunotherapy
Neoplasms*

Substances

Antibodies, Bispecific